The DPP9 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line, designed to eliminate functional expression of the DPP9 gene. This polyclonal pool, generated by CRISPR/Cas9-mediated gene disruption, provides a heterogeneous loss-of-function model suitable for studying DPP9-dependent cellular processes. The knockout eliminates dipeptidyl peptidase 9 protease activity, enabling researchers to investigate its roles in inflammasome regulation, pyroptosis, and cancer cell biology without clonal selection artifacts.
The host A-549 cell line, originally isolated from a 58-year-old Caucasian male with lung carcinoma, displays an adherent epithelial morphology and is widely employed as a model system for human lung adenocarcinoma research, cancer biology, and drug screening. These cells retain key signaling pathways relevant to tumorigenesis, including those associated with growth factor responses and cellular stress. The DPP9 knockout in this context provides a physiologically relevant platform to dissect molecular mechanisms underlying lung cancer progression and inflammatory cell death.
DPP9 encodes a cytosolic serine protease that functions as a critical negative regulator of the NLRP1 inflammasome. It restricts inflammasome assembly by cleaving the N-terminal domain of NLRP1, thereby preventing spontaneous procaspase-1 activation, ASC speck formation, and pyroptosis. The protease interacts directly with NLRP1 and CARD8, and its activity is modulated by upstream cellular stress signals and cytokines. Downstream, DPP9 loss derepresses NLRP1, leading to caspase-1-mediated maturation of IL-1?? and gasdermin D-dependent pyroptosis, and also influences expression of targets such as CXCL10 and NPY. Additionally, DPP9 has been implicated in mTOR signaling and apoptosis pathways, positioning it at the intersection of cell survival and inflammatory responses.
In A-549 cells, DPP9 knockout triggers constitutive NLRP1 activation, culminating in pyroptotic cell death and significant alterations in cell adhesion and proliferation. This phenotype mirrors key aspects of inflammasome-driven pathologies and highlights the importance of DPP9 in maintaining cellular homeostasis in lung epithelial cells. The knockout model thus serves as a powerful tool for investigating how dysregulated DPP9 activity contributes to lung adenocarcinoma biology and inflammatory disease mechanisms, including the interplay between chronic inflammation and tumor microenvironment remodeling.
This polyclonal knockout cell product is suited for a variety of research applications, including mechanistic studies of NLRP1 inflammasome regulation, pyroptosis signaling, and DPP9??s role in cancer cell migration and invasion. Typical assays include western blotting for NLRP1, CASP1, and cleaved gasdermin D; ELISA for IL-1?? secretion; LDH release assays to quantify pyroptotic death; cell viability and proliferation analyses; and immunofluorescence to visualize ASC speck formation. The cells also support drug target validation and screening strategies aimed at modulating inflammasome activity in lung cancer. For additional details or custom requests, please contact Ascent Research.
